<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.peertechzpublications.org/assets/xsl/oaitohtml.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
										<responseDate>2026-04-20T02:50:27Z</responseDate>
										<request verb="GetRecord" metadataPrefix="oai_dc" identifier="oai:www.peertechzpublications.org:10.17352/2581-4265.000065">https://www.peertechzpublications.org/oai-pmh</request><GetRecord><record>
								<header>
									<identifier>oai:www.peertechzpublications.org:10.17352/2581-4265.000065</identifier>
									<datestamp>2023-12-30</datestamp>
									<setSpec>PTZ.ANPC:VOL9</setSpec>
								</header>
								<metadata>
									<oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
										<dc:title>
										Improving measured health-related quality of life with outpatient high-dose methotrexate regimen among oncology patients with intracranial metastases: A systematic assessment
										</dc:title><dc:creator>Heun Min</dc:creator><dc:creator> Elizabeth Weil</dc:creator><dc:creator> Maggie Nelson</dc:creator><dc:creator> John Charlson</dc:creator><dc:creator> Yee Chung Cheng</dc:creator><dc:creator> Lubna N Chaudhary</dc:creator><dc:creator> John Burfeind</dc:creator><dc:creator> Janet Retseck</dc:creator><dc:creator> Deepika Sriram</dc:creator><dc:creator>Sailaja Kamaraju</dc:creator><dc:description>&lt;p&gt;Intracranial metastases including leptomeningeal disease are not uncommon in patients with metastatic solid tumor cancers, such as breast and sarcoma.&amp;nbsp; Treatment options are limited with disease progression on standard-of-care therapies, and high-dose Methotrexate (MTX) is offered for patients with well-preserved performance status. However, standard high-dose MTX treatment entails a lengthy hospitalization and close monitoring which can limit Quality of Life (QoL) for patients who already have multiple provider visits. The impact of high-dose MTX on patients’ daily lives has not yet been qualitatively examined. As a quality improvement project, our team designed an outpatient high-dose protocol for patients who tolerated at least one cycle of inpatient high-dose MTX, and herein we describe the protocol and a quality survey with patients’ feedback.&amp;nbsp; The purpose of this study is to explore and compare the influence of high-dose MTX treatments in two different settings – inpatient and ambulatory – on patients’ QoL. Second, we aim to identify recurrent themes defining patients’ perceived QoL and healthcare experiences. This study identified key QoL impacts that high-dose MTX treatments have on metastatic breast and sarcoma patients. Patients experienced decreased health-related burdens and improved social and psychosocial well-being associated with high-dose MTX treatment compared to standard inpatient treatment. This study provides an opportunity to identify recurrent thematic domains defining QoL in women with metastatic breast cancer.&lt;/p&gt;</dc:description>
										<dc:publisher>Archives of Nursing Practice and Care - Peertechz Publications</dc:publisher>
										<dc:date>2023-12-30</dc:date>
										<dc:type>Research Article</dc:type>
										<dc:identifier>https://doi.org/10.17352/2581-4265.000065</dc:identifier>
										<dc:language>en</dc:language>
										<dc:rights>Copyright © Heun Min et al.</dc:rights>
									</oai_dc:dc>
								</metadata>
							</record></GetRecord>
						</OAI-PMH>
